@igyxos.com
Igyxos Biotherapeutics is harnessing breakthrough science in monoclonal antibodies to pioneer novel therapeutics that aim to transform the treatment of infertility in men and women.
📢
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
PNG
About
Description
Igyxos Biotherapeutics is a pioneering French biotechnology company focused on revolutionizing infertility treatment. With a singular focus on infertility, Igyxos is dedicated to addressing the global need for improved solutions in this field. By developing novel therapeutics, they aim to make treatment more effective and efficient for both men and women.
Their groundbreaking approach involves the use of monoclonal antibodies (mAb) that bind to and enhance the activity of gonadotropins, hormones crucial for reproduction. This not only improves their effectiveness but also overcomes the limitations that have hindered the success rates of current infertility treatments. Igyxos' unique scientific approach offers new hope in overcoming infertility.
What sets Igyxos apart is the exceptional team they have assembled, consisting of experts in fertility research and monoclonal antibody therapeutics. Led by founder and chief scientific officer, Dr. Marie-Christine Maurel, their team has extensive experience in the field and has successfully discovered a lead antibody class that significantly improves receptor binding and activity.
Supported by Series A funding from notable investors such as BPI France, Go Capital, and UI Investissement, Igyxos is focused on advancing their clinical development program. Their vision is to transform infertility treatment and ultimately enhance patients' outcomes
Company Type
Privately Held
Company Size
2-10
Year Founded
2017
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere 👋
All services online